Skip to main content
Clinical Trials/NCT03552146
NCT03552146
Unknown
N/A

Evaluation of the Effects on Efficiency of a Sedation Service by Switching From Propofol to Dexmedetomidine

Children's Healthcare of Atlanta1 site in 1 country60 target enrollmentJuly 24, 2018

Overview

Phase
N/A
Intervention
Propofol
Conditions
Sedative Adverse Reaction
Sponsor
Children's Healthcare of Atlanta
Enrollment
60
Locations
1
Primary Endpoint
Procedural times to achieve optimal sedation
Last Updated
6 years ago

Overview

Brief Summary

The primary purpose of this observational study is to compare what drugs work best in sedating children (> 3 months to < 36 months) who need an MRI. This type of research may help clinicians (healthcare providers) learn more about how dexmedetomidine works compared to propofol. The investigators are planning to have 60 children complete the study at Children's Healthcare of Atlanta at Scottish Rite. Half (30) of the patients will be randomized to receive dexmedetomidine and the other half will receive propofol. (Both drugs are licensed and approved for the sedation performed for consented patients.)

Detailed Description

There are several different medications commonly being used to facilitate the administration of radiologic procedures on children. Procedures such as Magnetic Resonance Imaging (MRIs) require that the patient remain still for the duration of the test. Propofol has become the drug of choice for many sedation services due to its rapid onset of action, rapid recovery time, ability to achieve sedation reliably and favorable safety profile. Dexmedetomidine, a selective alpha-2- adrenergic agonist, has also gained popularity with sedation services. Its main advantage over propofol is that it has minimal respiratory complications when compared to propofol. The sedative effect from dexmedetomidine preserves a natural sleep pattern and induces cooperative sedation in which patients are easily arousable. In pediatric studies, the most frequent adverse effect have been related to its potential to cause hypotension and bradycardia, which resolve with dose reduction. Additionally, dexmedetomidine does not seem to have as much impairment of cognitive function and has an opioid sparing effect. Dexmedetomidine, however, has a longer onset of action and longer recovery time compared to propofol, which has limited its use with many sedation services.

Registry
clinicaltrials.gov
Start Date
July 24, 2018
End Date
September 30, 2019
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

David Fagin, MD

Assistant Medical Director

Children's Healthcare of Atlanta

Eligibility Criteria

Inclusion Criteria

  • Patient (or Parent/Guardian) is English speaking
  • Patient is undergoing a scheduled, elective non-contrast MRI of the brain
  • Patient is \> 3 months to \<36 months of age

Exclusion Criteria

  • Patients undergoing MRI with contrast
  • Patients older than 36 months of age or younger than 3 months of age
  • Patients presenting to Emergency Department (ED) out of screening hours
  • Patients who are not English speaking
  • Patients who have history or record of propofol or dexmedetomidine allergy
  • Patients with known or history of anaphylaxis to eggs, egg products, soybeans, or soy based products; if patient has a history of a hypersensitivity reaction associated with exposure to eggs, egg products, soybeans, or soy based products, approval must be given by the treating attending physician and documented on the patient's medical record.
  • Patients with unstable cardiac or respiratory status as determined by treating attending physician
  • Patients who are receiving digoxin

Arms & Interventions

Sedation Group 1

Patients will receive standard of care dose of Propofol, based on the provider's assessment, prior to radiologic procedure.

Intervention: Propofol

Sedation Group 2

Patients will receive standard of care dose of dexmedetomidine, based on the provider's assessment, prior to radiologic procedure.

Intervention: Dexmedetomidine

Outcomes

Primary Outcomes

Procedural times to achieve optimal sedation

Time Frame: Start of procedure to discharge (up to 8 hours)

Measuring the amount of time it takes for a patient to be discharged starting from induction (start of infusion).

Secondary Outcomes

  • Sedation related events(Start of procedure to up to 36 hours post-discharge)

Study Sites (1)

Loading locations...

Similar Trials